Mizagliflozin

From WikiProjectMed
Jump to navigation Jump to search
Mizagliflozin
Legal status
Legal status
  • Investigational
Identifiers
  • 2,2-dimethyl-3-[3-[3-methyl-4-[[5-propan-2-yl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1H-pyrazol-4-yl]methyl]phenoxy]propylamino]propanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC28H44N4O8
Molar mass564.680 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)OCCCNCC(C)(C)C(=O)N)CC2=C(NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)C(C)C
  • InChI=1S/C28H44N4O8/c1-15(2)21-19(25(32-31-21)40-26-24(36)23(35)22(34)20(13-33)39-26)12-17-7-8-18(11-16(17)3)38-10-6-9-30-14-28(4,5)27(29)37/h7-8,11,15,20,22-24,26,30,33-36H,6,9-10,12-14H2,1-5H3,(H2,29,37)(H,31,32)/t20-,22-,23+,24-,26+/m1/s1
  • Key:LREHMKLEOJAVMQ-TXKDOCKMSA-N

Mizagliflozin is an SGLT2 inhibitor developed as a potential treatment for chronic constipation.[1][2] It progressed as far as Phase II trials in humans but was not approved for medical use, however it has since been investigated for other applications.[3][4]

References

  1. ^ Inoue T, Takemura M, Fushimi N, Fujimori Y, Onozato T, Kurooka T, et al. (July 2017). "Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation". European Journal of Pharmacology. 806: 25–31. doi:10.1016/j.ejphar.2017.04.010. PMID 28410751.
  2. ^ Fukudo S, Endo Y, Hongo M, Nakajima A, Abe T, Kobayashi H, et al. (September 2018). "Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial". The Lancet. Gastroenterology & Hepatology. 3 (9): 603–613. doi:10.1016/S2468-1253(18)30165-1. PMID 30056028.
  3. ^ Ishida N, Saito M, Sato S, Tezuka Y, Sanbe A, Taira E, et al. (October 2021). "Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease". Pharmacology Research & Perspectives. 9 (5): e00869. doi:10.1002/prp2.869. PMC 8480397. PMID 34586752.
  4. ^ Tsunokake S, Iwabuchi E, Miki Y, Kanai A, Onodera Y, Sasano H, et al. (October 2023). "SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast". Breast Cancer Research and Treatment. 201 (3): 499–513. doi:10.1007/s10549-023-07024-9. PMID 37439959.
Retrieved from "https://mdwiki.org/wiki/Mizagliflozin"